Indoco Remedies Ltd (INDOCO) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Indoco Remedies Ltd on NSE and BSE, with an AI summary of each filing.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ms. Aditi M Panandikar & Ms. Madhura Suresh Kare
Acquisition/ Disposal of Shares · 04 Nov 2026, 8:20 pm
Indoco Remedies Promoters Acquire Shares via Open Market Promoter group members Aditi M. Panandikar and Madhura Suresh Kare acquired a combined 5,996 equity shares (0.006% stake) of Indoco Remedies Limited through open market purchases on 3rd Nov'26. Individually, Aditi Panandikar bought 3,000 shares (increasing holding from 3.177% to 3.180%), while Madhura Kare acquired 2,996 shares (increasing holding from 2.703% to 2.706%). Following this transaction, their collective shareholding in the company increased from 54,28,545 shares (5.880%) to 54,34,541 shares (5.887%) out of a total equity base of 9,23,18,455 shares.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi M Panandikar & Others
Acquisition/ Disposal of Shares · 03 Nov 2026, 11:15 pm
Promoters Acquire Additional Stake in Indoco Remedies via Open Market Indoco Remedies' promoter group members, Aditi M. Panandikar and Madhura Suresh Kare, acquired 8,004 equity shares (0.009% stake) via open market purchases between 30th Oct'26 and 2nd Nov'26. Individually, Aditi Panandikar bought 4,000 shares, increasing her stake from 3.173% (29,29,128 shares) to 3.177% (29,33,128 shares), while Madhura Kare acquired 4,004 shares, raising her holding from 2.699% (24,91,413 shares) to 2.703% (24,95,417 shares). Consequently, their combined promoter holding increased from 5.872% (54,20,541 shares) to 5.880% (54,28,545 shares). Total equity share capital remains unchanged at 9,23,18,455 shares.
Transcript of Earnings Conference Call on Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30-09-2026
Transcript · 29 Oct 2026, 9:49 pm
Audio recording of Earnings Conference Call on Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended 30th September, 2026
Audio / Video · 27 Oct 2026, 10:45 pm
Indoco Remedies Releases Earnings Call Audio Recording for Q2 & H1 FY27 Indoco Remedies has uploaded the audio recording of its earnings conference call held on 27th Oct'26 discussing the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. The call took place from 3:00 PM to 4:05 PM IST, and the complete audio is accessible to investors via the company’s official website under the investor concall transcripts section in compliance with SEBI LODR regulations.
Indoco''s Clinical Research Orgainsation - AnaCipher receives approval from ANVISA Brazil for its clinical and bioanalytical facilities
Press Release · 27 Oct 2026, 9:07 pm
Indoco’s CRO AnaCipher Secures ANVISA Brazil Regulatory Approval Indoco Remedies announced that its clinical research organisation, AnaCipher, received regulatory approval from Brazil’s ANVISA for its clinical and bioanalytical facilities following an inspection conducted from 30th Mar'26 to 7th Apr'26. The approval authorizes AnaCipher to conduct Bioavailability and Bioequivalence studies and provide bioanalytical support for regulatory submissions in Brazil. This clearance strengthens AnaCipher’s international compliance profile, enabling Indoco to expand its contract research services across Latin American markets and support global pharmaceutical clients.
Approval of the Financial Results for the Quarter and Half Year Ended 30th September, 2026
Financial Result · 27 Oct 2026, 6:21 pm
Indoco Remedies Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 27 Oct 2026, 6:17 pm
Indoco Remedies Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 52,017 (+7.3% YoY | +11.3% QoQ) ■ EBITDA: 4,643 (+7.9% YoY | +13.2% QoQ) ■ EBITDA Margin (%): 8.9 (+4 bps YoY | +15 bps QoQ) ■ PAT: 1,838 (Loss to Profit YoY | -71.7% QoQ) ■ EPS (INR): 2.11 (Loss to Profit YoY | -70.2% QoQ)
Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby inform you that the Board ....
Outcome · 27 Oct 2026, 6:17 pm
Indoco Remedies Posts Q2FY27 Results with Consolidated Revenue Growth of 7.4% YoY Indoco Remedies reported consolidated revenue from operations of ₹506.92 crore for the quarter ended 30th Sep'26, up 7.4% YoY from ₹471.83 crore. Consolidated net profit swung to ₹19.47 crore compared to a net loss of ₹9.21 crore in the year-ago period, supported by exceptional gains of ₹37.14 crore from property and trademark transactions. EBITDA reached ₹46.40 crore (9.2% margin). Standalone revenue stood at ₹438.06 crore with a net profit of ₹30.63 crore. For H1FY27, consolidated revenue grew 7.8% YoY to ₹973.14 crore.
Pursuant to Regulation 30 of SEBI LODR, this is to inform you that the Nomination and Remuneration Committee in its meeting held today i.e. 27th October, 2026 has approved the allotment ....
Others (Uncategorized) · 27 Oct 2026, 3:31 pm
Indoco Remedies Approves Allotment of 14,850 Equity Shares Under ESOP Plan The Nomination and Remuneration Committee of Indoco Remedies approved the allotment of 14,850 equity shares (face value Rs. 2 each) to the Indoco Employees Welfare Trust under its Employee Stock Option Plan–2022 on 27th Oct'26. The shares were issued at an exercise price of Rs. 2 each, totaling Rs. 29,700. Consequently, the company's paid-up equity share capital increased from Rs. 18,46,07,210 (9,23,03,605 shares) to Rs. 18,46,36,910 (9,23,18,455 shares).
Intimation of Earnings Conference Call on Unaudited Financial Results for Quarter and Half year ended 30th September 2026
Intimation · 27 Oct 2026, 3:00 pm
Indoco Remedies Schedules Q2 FY27 Earnings Conference Call Indoco Remedies Limited will host its Q2 FY27 earnings conference call on 27th Oct'26 at 3:00 PM IST to discuss unaudited financial results for the quarter and half year ended 30th Sep'26. The call will be hosted by Dolat Capital Market and attended by key management personnel, including Managing Director Aditi Panandikar, Joint Managing Director Sundeep V. Bambolkar, and CFO Pramod Ghorpade. Universal dial-in numbers include +91 22 6280 1116 and +91 22 7115 8017, alongside international toll-free options.
INDOCO REMEDIES LIMITED has informed the Exchange about Board Meeting to be held on 27-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 27 Oct 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 27 Oct 2026, 5:30 am
Indoco Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve A meeting of the Board of Directors ....
Intimation · 27 Oct 2026, 5:30 am
Indoco Remedies Schedules Board Meeting to Approve Q2 and H1 FY27 Results Indoco Remedies Limited has scheduled a meeting of its Board of Directors on 27th Oct'26 to consider and approve the un-audited standalone and consolidated financial results for the quarter and half year ended 30th Sep'26. Consequently, the trading window for dealing in the company's equity shares remains closed for designated persons and their immediate relatives until 29th Oct'26, concluding 48 hours post the declaration of the financial results.
Pursuant to Regulation 30 and Part A of Schedule III of SEBI (LODR) Regulations,2015, please find enclosed a copy of the letter dispatched to shareholders holding shares in physical mode, ....
Others (Uncategorized) · 29 Sept 2026, 9:27 pm
Indoco Remedies Issues Mandatory KYC and Demat Compliance Notice to Physical Shareholders Indoco Remedies Limited dispatched reminders to physical mode shareholders on 29th Sep'26 to mandatorily submit PAN, KYC, mobile number, specimen signature, and bank details to RTA MUFG Intime India. Per SEBI directives, failure to update these details restricts lodging grievances, processing service requests, and receiving electronic dividend, interest, or redemption payments. Additionally, with physical share transfers prohibited since 1st Apr'19 and dividends strictly payable via electronic mode, the company urged physical holders to dematerialize shares promptly to ensure market liquidity and smooth corporate payouts.
Pursuant to Regulation 30 of the SEBI (LODR) Regulations,2015, please note that the Company received intimation today that the Wholly Owned Subsidiary of the Company in the name and style ....
Others (Uncategorized) · 29 Sept 2026, 2:28 am
Indoco Remedies Incorporates Wholly Owned Subsidiary Warren Lifesciences Indoco Remedies has incorporated a wholly owned subsidiary, Warren Lifesciences Private Limited (WLPL), on 26th Sep'26. Indoco holds a 100% equity stake in WLPL, subscribing to 10,000 equity shares of Rs. 10 each for an aggregate cash consideration of Rs. 1,00,000. WLPL operates within the pharmaceutical sector with core business objectives to develop, manufacture, and sell active pharmaceutical ingredients (APIs), finished formulations, and key starting materials. As a newly registered entity, WLPL is yet to commence commercial operations.
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015-ESG rating
Others (Uncategorized) · 24 Sept 2026, 6:20 pm
Crisil Assigns 'Crisil ESG 60' Rating to Indoco Remedies Indoco Remedies announced on 24th Sep'26 that Crisil ESG Ratings & Analytics Limited has assigned an ESG rating of "Crisil ESG 60" to the company. The evaluation was independently conducted by Crisil based entirely on publicly available information, with no formal engagement commissioned by Indoco Remedies.
Pursuant to Regulation 30 of SEBI LODR, the Committee of Executive Directors in its meeting held today i.e. 18th September, 2026 has considered and approved the incorporation of the wholly ....
Others (Uncategorized) · 18 Sept 2026, 11:26 pm
Indoco Remedies Approves Incorporation of Wholly Owned Subsidiary Warren Lifesciences Indoco Remedies' Committee of Executive Directors approved the incorporation of a wholly owned subsidiary, Warren Lifesciences Private Limited, on 18th Sep'26 following name approval from the ROC, Mumbai. The new entity will operate in the pharmaceutical sector, focusing on manufacturing, developing, and selling active pharmaceutical ingredients (APIs), finished formulations, and key starting materials. Indoco Remedies will hold a 100% stake via cash subscription, with a proposed authorized and paid-up equity share capital of Rs. 1,00,000 comprising 10,000 equity shares at Rs. 10 each.
Please find enclosed herewith the details of Voting Results and Scrutinizers Report for the 79th AGM of the Company held on 17th September, 2026
Annual General Meeting · 18 Sept 2026, 6:58 pm
We are submitting herewith the details regarding the Proceedings of the 79th AGM of the Company held on Thursday, 17th September, 2026 at 10.30 am through video conferencing(VC)/other audio ....
Annual General Meeting · 17 Sept 2026, 6:34 pm
UK MHRA inspection at Company''s manufacturing facility at Plant I (solid oral dosage form) located at Goa.
Others (Uncategorized) · 10 Sept 2026, 6:08 pm
Indoco Remedies Clears UK MHRA Inspection for Goa Plant I Facility UK MHRA conducted a cGMP inspection at Indoco Remedies' Plant I solid oral dosage manufacturing facility in Goa from 7th Sep'26 to 9th Sep'26. The inspection concluded with zero critical or major observations. The Goa facility supplies key regulated markets, including the UK, Europe, South Africa, Australia, New Zealand, and Canada, and is projected to contribute approximately 30% of the company's total international business. The site also maintains regulatory approvals from USFDA, TGA-Australia, EU Malta (MMA), SAHPRA, and WHO-GMP.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi M Panandikar & Others
Acquisition/ Disposal of Shares · 10 Sept 2026, 3:05 pm
Indoco Remedies Promoters Acquire 38,930 Shares via Open Market Indoco Remedies Limited promoter group members—Aditi M. Panandikar, Madhura Suresh Kare, Suresh G. Kare, and Aruna Suresh Kare—acquired 38,930 equity shares (0.04% stake) through open market purchases on 8th Sep'26 and 9th Sep'26. Following this transaction, the collective holding of the acquirers increased from 67,03,612 equity shares (7.26%) to 67,42,542 equity shares (7.30% of total voting capital). The company's total equity share capital remains unchanged at Rs. 18.46 crore, divided into 9,23,03,605 equity shares of Rs. 2 face value each.
USFDA inspection at Company''s manufacturing facility at Plant II (Sterile) located at Goa.
Others (Uncategorized) · 05 Sept 2026, 7:11 pm
Indoco Remedies Receives Seven USFDA Observations for Goa Sterile Facility Indoco Remedies received seven Form 483 observations following a USFDA inspection of its sterile manufacturing facility at Plant II in Goa, conducted between 27th Aug'26 and 4th Sep'26. The company stated it is addressing the observations comprehensively and plans to submit its response to the regulator within the stipulated timeframe.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi Panandikar & Others
Acquisition/ Disposal of Shares · 03 Sept 2026, 3:37 pm
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi M Panandikar & Others
Acquisition/ Disposal of Shares · 01 Sept 2026, 4:16 pm
Intimation of execution of Deed of Conveyance for Sale of Company''s plot of land.
Others (Uncategorized) · 27 Aug 2026, 9:31 pm
Indoco Remedies to Realize INR 64 Crore from Mumbai Land Sale Indoco Remedies executed a Deed of Conveyance on 27 Aug '26 to sell a land plot in Mumbai to Kalpataru Townships Private Limited. The transaction is valued at INR 64 crore for a 2,876.08 sq. meter built-up area in Mahal Industrial Estate, Andheri. The company stated this sale of a non-core asset will have no impact on its business operations and does not constitute a substantial undertaking. The transaction is not a related party transaction and no conflict of interest is expected.